L. , inhibition de la CETP et du diabète de type 2 sur les niveaux plasmatiques de PCSK9 et de Lp(a) chez les patients à haut risque cardiovasculaire

J. Benoit, F. Arsenault, F. Petrides, W. Tabet, K. Bao et al., Journal of Clinical Lipidology, vol.12, pp.130-136, 2018.

S. Ramin-mangata, M. Wargny, M. Pichelin, L. May, C. Thédrez et al., Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes, Atherosclerosis. 2020, vol.293, pp.49-56

, CD93 is a cell surface lectin receptor involved in the control of the inflammatory response stimulated by exogenous DNA

B. Nativel, S. Ramin-mangata, R. Mevizou, A. Figuester, J. Andries et al., , vol.158, pp.85-93, 2019.

M. Blanchard, I. Croyal, S. Khantalin, K. Ramin-mangata, B. Chemello et al., Reduced Lipoprotein(a) associated with the apolipoprotein E2 genotype confers cardiovascular protection in Familial Hypercholesterolemia V, JACC Basic Transl Sci. 2019, vol.24, pp.425-427

, PCSK9: from biology to clinical applications

V. Blanchard, I. Khantalin, S. Ramin-mangata, K. Chémello, B. Nativel et al., , vol.51, pp.177-183, 2018.

, Key aspects of PCSK9 inhibition beyond LDL lowering

S. Ramin-mangata, V. Blanchard, and G. Lambert, Curr Opin Lipidol, vol.29, pp.453-458, 2018.

M. Croyal, T. T. Tran, R. H. Blanchard, L. Bail, J. C. Villard et al., Clin Sci (Lond), vol.132, pp.1075-1083, 2018.

, Kinetics of plasma apolipoprotein E isoforms by LC-MS/MS: a pilot study

V. Blanchard, S. Ramin-mangata, S. Billon-crossouard, A. Aguesse, M. Durand et al., J Lipid Res, vol.59, pp.892-900, 2018.

, Homozygous FH Patients with Identical Mutations Variably Express the LDL Receptor: Implications for the Efficacy of Evolocumab

A. Thedrez, D. Blom, S. Ramin-mangata, V. Blanchard, M. Croyal et al., Arterioscler Thromb Vasc Biol, vol.38, pp.592-598, 2018.

, Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk

B. J. Arsenault, F. Petrides, F. Tabet, W. Bao, G. K. Hovingh et al., J Clin Lipidol, vol.12, pp.130-136, 2017.

Z. Kaabia, L. León, S. Ramin-mangata, T. Baty, F. Fall et al., Fenofibrate decreases plasma ceramide in type 2 diabetes patients: A novel marker of CVD? Croyal M, vol.44, pp.143-149, 2017.

, Risk Factors of Extended-Spectrum ?-Lactamase Producing Enterobacteriaceae Occurrence in Farms in Reunion, Madagascar and Mayotte Islands, pp.2016-2017

N. Gay, A. Leclaire, M. Laval, G. Miltgen, M. Jégo et al., , 2018.

, The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies

G. Lambert, A. Thedrez, M. Croyal, S. Ramin-mangata, D. Couret et al., Clin Sci, vol.131, pp.261-268, 2017.

, Expression and function of PCSK9 in human pancreatic beta cells POSTER, Participation à des congrès ORAL -American Heart Association, vol.2019

E. D. Abel, O. Peroni, J. K. Kim, Y. B. Kim, O. Boss et al., Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver, Nature, vol.409, pp.729-733, 2001.

M. Abifadel, M. Varret, J. Rabès, D. Allard, K. Ouguerram et al., Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Nat. Genet, vol.34, pp.154-156, 2003.

W. E. Alborn, G. Cao, H. E. Careskey, Y. Qian, D. R. Subramaniam et al., Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol, Clin. Chem, vol.53, pp.1814-1819, 2007.

S. W. Altmann, H. R. Davis, L. Zhu, X. Yao, L. M. Hoos et al.,

M. Maguire, A. Golovko, and M. Zeng, Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption, Science, vol.303, pp.1201-1204, 2004.

, Diagnosis and classification of diabetes mellitus, Diabetes Care, vol.37, issue.1, pp.81-90, 2014.

B. J. Arsenault, F. Petrides, F. Tabet, W. Bao, G. K. Hovingh et al., Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk, J Clin Lipidol, vol.12, pp.130-136, 2018.

H. J. Avis, B. A. Hutten, C. Gagné, G. Langslet, B. W. Mccrindle et al.,

J. J. Kastelein and E. A. Stein, Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia, J. Am. Coll. Cardiol, vol.55, pp.1121-1126, 2010.

Z. Awan, N. G. Seidah, J. G. Macfadyen, S. Benjannet, D. I. Chasman et al.,

J. Genest, Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial, Clin. Chem, vol.58, pp.183-189, 2012.

A. Baass, G. Dubuc, M. Tremblay, E. E. Delvin, J. O'loughlin et al.,

M. Lambert, Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents, Clin. Chem, vol.55, pp.1637-1645, 2009.

C. M. Ballantyne, J. Neutel, A. Cropp, W. Duggan, E. Q. Wang et al.,

N. Kaila, J. Vincent, and H. Bays, Results of Bococizumab, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia, vol.9, pp.1212-1221, 2015.

M. Benazra, M. Lecomte, C. Colace, A. Müller, C. Machado et al., A human beta cell line with drug inducible excision of immortalizing transgenes, Mol Metab, vol.4, pp.916-925, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01298792

S. Benjannet, D. Rhainds, R. Essalmani, J. Mayne, L. Wickham et al.,

J. Hamelin, M. Varret, and D. Allard, NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol, J. Biol. Chem, vol.279, pp.48865-48875, 2004.

S. Benjannet, D. Rhainds, J. Hamelin, N. Nassoury, and N. G. Seidah, The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications, J. Biol. Chem, vol.281, pp.30561-30572, 2006.

K. E. Berge, L. Ose, and T. P. Leren, Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy, 2006.

, Arterioscler. Thromb. Vasc. Biol, vol.26, pp.1094-1100

J. Besseling, J. J. Kastelein, J. C. Defesche, B. A. Hutten, and G. K. Hovingh, , 2015.

, Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus, JAMA, vol.313, pp.1029-1036

D. J. Betteridge and R. Carmena, The diabetogenic action of statins -mechanisms and clinical implications, Nature Reviews Endocrinology, vol.12, pp.99-110, 2016.

V. Blanchard, I. Khantalin, S. Ramin-mangata, K. Chémello, B. Nativel et al., PCSK9: from biology to clinical applications, 2018.

D. J. Blom, T. Hala, M. Bolognese, M. J. Lillestol, P. D. Toth et al., A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia, 2014.

D. J. Blom, M. J. Koren, E. Roth, M. L. Monsalvo, C. S. Djedjos et al.,

S. M. Wasserman, C. M. Ballantyne, and R. R. Holman, Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome, Diabetes Obes Metab, vol.19, pp.98-107, 2017.

J. Borén and K. J. Williams, The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity, Curr. Opin. Lipidol, vol.27, pp.473-483, 2016.

J. Borén, K. Olin, I. Lee, A. Chait, T. N. Wight et al., Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding, J. Clin. Invest, vol.101, pp.2658-2664, 1998.

H. B. Brewer, Current concepts of the molecular structure and metabolism of human apolipoproteins and lipoproteins, Klin. Wochenschr, vol.59, pp.1023-1035, 1981.

M. C. Brouwers, J. S. Troutt, M. M. Van-greevenbroek, I. Ferreira, E. J. Feskens et al., , 2011.

, Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study, Atherosclerosis, vol.217, pp.263-267

M. S. Brown and J. L. Goldstein, Expression of the Familial Hypercholesterolemia Gene in Heterozygotes: Mechanism for a Dominant Disorder in Man, Science, vol.185, pp.61-63, 1974.

M. S. Brown and J. L. Goldstein, The SREBP Pathway: Regulation of Cholesterol Metabolism by Proteolysis of a Membrane-Bound Transcription Factor, Cell, vol.89, pp.331-340, 1997.

M. S. Brown and J. L. Goldstein, Cholesterol feedback: from Schoenheimer's bottle to Scap's MELADL, J. Lipid Res, vol.50, pp.15-27, 2009.

M. S. Brown, S. E. Dana, and J. L. Goldstein, Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts by lipoproteins, Proc. Natl. Acad. Sci, 1973.

U. S. , , vol.70, pp.2162-2166

M. S. Brown, S. E. Dana, and J. L. Goldstein, Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia, J. Biol. Chem, vol.249, pp.789-796, 1974.

M. S. Brown, J. R. Faust, J. L. Goldstein, I. Kaneko, and A. Endo, Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase, J. Biol. Chem, vol.253, pp.1121-1128, 1978.

L. R. Brunham, J. K. Kruit, T. D. Pape, J. M. Timmins, A. Q. Reuwer et al.,

B. Rodrigues, J. D. Johnson, and J. S. Parks, Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment, Nat. Med, vol.13, pp.340-347, 2007.

N. L. Bucher, P. Overath, and F. Lynen, beta-Hydroxy-beta-methyl-glutaryl coenzyme A reductase, cleavage and condensing enzymes in relation to cholesterol formation in rat liver, Biochim. Biophys. Acta, vol.40, pp.491-501, 1960.

J. R. Burnett, J. Shan, B. A. Miskie, A. J. Whitfield, J. Yuan et al.,

R. A. Hegele and Z. Yao, A novel nontruncating APOB gene mutation, R463W, causes familial hypobetalipoproteinemia, J. Biol. Chem, vol.278, pp.13442-13452, 2003.

A. E. Butler, J. Janson, S. Bonner-weir, R. Ritzel, R. A. Rizza et al., Betacell deficit and increased beta-cell apoptosis in humans with type 2 diabetes, Diabetes, vol.52, pp.102-110, 2003.

J. Cameron, Ø. L. Holla, T. Ranheim, M. A. Kulseth, K. E. Berge et al., , 2006.

, Effect of mutations in the PCSK9 gene on the cell surface LDL receptors, Hum. Mol. Genet, vol.15, pp.1551-1558

C. P. Cannon, E. Braunwald, C. H. Mccabe, D. J. Rader, J. L. Rouleau et al.,

K. A. Hill, M. A. Pfeffer, and A. M. Skene, Intensive versus moderate lipid lowering with statins after acute coronary syndromes, N. Engl. J. Med, vol.350, pp.1495-1504, 2004.

C. P. Cannon, M. A. Blazing, R. P. Giugliano, A. Mccagg, J. A. White et al., Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes, New England Journal of Medicine, vol.372, pp.2387-2397, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01258957

Y. Cao, H. Liu, Q. Dong, S. Li, and J. Li, Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis, Diabetes Obes Metab, vol.20, pp.1391-1398, 2018.

H. E. Careskey, R. A. Davis, W. E. Alborn, J. S. Troutt, G. Cao et al., , 2008.

, Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9, J. Lipid Res, vol.49, pp.394-398

B. Cariou, M. Le-bras, C. Langhi, C. Le-may, B. Guyomarc'h-delasalle et al.,

P. Costet, Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients, Atherosclerosis, vol.211, pp.700-702, 2010.

L. S. De-carvalho, A. M. Campos, and A. C. Sposito, Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years, Diabetes Care, vol.41, pp.364-367, 2018.

F. Castriota, L. Rieswijk, S. Dahlberg, L. Merrill, M. A. Steinmaus et al., A State-of-the-Science Review of Arsenic's Effects on Glucose Homeostasis in Experimental Models, Environ Health Perspect, vol.128, 2020.

G. R. Castro and C. J. Fielding, Early incorporation of cell-derived cholesterol into prebeta-migrating high-density lipoprotein, Biochemistry, vol.27, pp.25-29, 1988.

D. C. Chan, J. Pang, B. M. Mcquillan, J. Hung, J. P. Beilby et al.,

, Plasma Proprotein Convertase Subtilisin Kexin Type 9 as a Predictor of Carotid Atherosclerosis in Asymptomatic Adults, Heart Lung Circ, vol.25, pp.520-525

J. C. Chan, D. E. Piper, Q. Cao, D. Liu, C. King et al., A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates, Proc. Natl. Acad. Sci. U.S.A, vol.106, pp.9820-9825, 2009.

M. J. Chapman, J. K. Stock, and H. N. Ginsberg, PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era, Curr Opin Lipidol, vol.26, pp.511-520, 2015.

A. Chaudhury, C. Duvoor, V. S. Reddy-dendi, S. Kraleti, A. Chada et al., Clinical Review of Antidiabetic Drugs: Implications for Type 2, Diabetes Mellitus Management. Front Endocrinol, 2017.

C. Chen, C. M. Cohrs, J. Stertmann, R. Bozsak, and S. Speier, Human beta cell mass and function in diabetes: Recent advances in knowledge and technologies to understand disease pathogenesis, Mol Metab, vol.6, pp.943-957, 2017.

L. Chen, D. J. Magliano, and P. Z. Zimmet, The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives, Nature Reviews Endocrinology, vol.8, pp.228-236, 2012.

C. Yung-chih, H. Alex, L. Kyaw-tin, S. Bobik, A. et al., , 2016.

. Atherosclerotic-plaque-rupture, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.36, pp.63-72

E. Y. Choe, Y. Cho, Y. Choi, Y. Yun, H. J. Wang et al., The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes, Diabetes & Metabolism Journal, vol.38, p.211, 2014.

. Clinvar,

J. Cohen, A. Pertsemlidis, I. K. Kotowski, R. Graham, C. K. Garcia et al., , 2005.

, Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9, Nat. Genet, vol.37, pp.161-165

J. C. Cohen, E. Boerwinkle, T. H. Mosley, and H. H. Hobbs, Sequence variations in PCSK9, low LDL, and protection against coronary heart disease, N. Engl. J. Med, vol.354, pp.1264-1272, 2006.

H. M. Colhoun, H. N. Ginsberg, J. G. Robinson, L. A. Leiter, D. Müller-wieland et al., , p.9, 2016.

, inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies, Eur. Heart J, vol.37, pp.2981-2989

F. Cosentino, P. J. Grant, V. Aboyans, C. J. Bailey, A. Ceriello et al., 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASDThe Task Force for diabetes, pre-diabetes, 2020.

, ESC) and the European Association for the Study of Diabetes (EASD), Eur Heart J, vol.41, pp.255-323

P. Costet, B. Cariou, G. Lambert, F. Lalanne, B. Lardeux et al.,

B. Staels and M. Krempf, Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c, J. Biol. Chem, vol.281, pp.6211-6218, 2006.

J. P. Crandall, K. Mather, S. N. Rajpathak, R. B. Goldberg, K. Watson et al., Statin use and risk of developing diabetes: results from the Diabetes Prevention Program, BMJ Open Diabetes Research and Care, vol.5, p.438, 2017.

Q. Cui, X. Ju, T. Yang, M. Zhang, W. Tang et al.,

R. T. Pickard, Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population, Atherosclerosis, vol.213, pp.632-636, 2010.

L. Da-dalt, M. Ruscica, F. Bonacina, G. Balzarotti, A. Dhyani et al., PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor, Eur. Heart J, 2018.

G. Da-silva-xavier, The Cells of the Islets of Langerhans, J Clin Med, vol.7, 2018.

R. T. Dadu and C. M. Ballantyne, Lipid lowering with PCSK9 inhibitors, Nature Reviews Cardiology, vol.11, pp.563-575, 2014.

T. F. Daniels, K. M. Killinger, J. J. Michal, R. W. Wright, and Z. Jiang, , 2009.

, Lipoproteins, cholesterol homeostasis and cardiac health, Int J Biol Sci, vol.5, pp.474-488

M. J. Davies, D. A. D'alessio, J. Fradkin, W. N. Kernan, C. Mathieu et al., , 2018.

, Diabetes, 2018.

, European Association for the Study of Diabetes (EASD), Diabetes Care, vol.41, pp.2669-2701

J. C. Defesche, C. Stefanutti, G. Langslet, P. N. Hopkins, W. Seiz et al.,

S. C. Hamon, P. Banerjee, and J. J. Kastelein, Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia, J Clin Lipidol, vol.11, pp.1338-1346, 2017.

S. Deng, M. Vatamaniuk, X. Huang, N. Doliba, M. Lian et al.,

N. M. Desai, B. Koeberlein, and B. Wolf, Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects, Diabetes, vol.53, pp.624-632, 2004.

C. S. Dias, A. J. Shaywitz, S. M. Wasserman, B. P. Smith, B. Gao et al., Effects of AMG 145 on lowdensity lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebocontrolled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins, J. Am. Coll. Cardiol, vol.60, pp.1888-1898, 2012.

M. R. Digruccio, A. M. Mawla, C. J. Donaldson, G. M. Noguchi, J. Vaughan et al., Comprehensive alpha, beta and delta cell transcriptomes reveal that ghrelin selectively activates delta cells and promotes somatostatin release from pancreatic islets, Molecular Metabolism, vol.5, pp.449-458, 2016.

M. H. Dominiczak and M. J. Caslake, Apolipoproteins: metabolic role and clinical biochemistry applications, Ann. Clin. Biochem, vol.48, pp.498-515, 2011.

M. Y. Donath, J. A. Ehses, K. Maedler, D. M. Schumann, H. Ellingsgaard et al., Mechanisms of ?-Cell Death in Type 2 Diabetes, Diabetes, vol.54, pp.108-113, 2005.

B. Dong, M. Wu, H. Li, F. B. Kraemer, K. Adeli et al., Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters, J. Lipid Res, vol.51, pp.1486-1495, 2010.

A. C. Doran, N. Meller, and C. A. Mcnamara, Role of smooth muscle cells in the initiation and early progression of atherosclerosis, Arterioscler. Thromb. Vasc. Biol, vol.28, pp.812-819, 2008.

J. S. Dron and R. A. Hegele, Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants, Curr. Opin. Lipidol, vol.28, pp.161-169, 2017.

D. J. Drucker and M. A. Nauck, The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes, Lancet, vol.368, pp.1696-1705, 2006.

G. Dubuc, A. Chamberland, H. Wassef, J. Davignon, N. G. Seidah et al., Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia, Arterioscler. Thromb. Vasc. Biol, vol.24, pp.1454-1459, 2004.

G. Dubuc, M. Tremblay, G. Paré, H. Jacques, J. Hamelin et al., A new method for measurement of total plasma PCSK9: clinical applications, J. Lipid Res, vol.51, pp.140-149, 2010.

C. J. Duff, M. J. Scott, I. T. Kirby, S. E. Hutchinson, S. L. Martin et al., , 2009.

, Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor, Biochem. J, vol.419, pp.577-584

M. El-mir, V. Nogueira, E. Fontaine, N. Avéret, M. Rigoulet et al., , 2000.

, Dimethylbiguanide Inhibits Cell Respiration via an Indirect Effect Targeted on the Respiratory Chain Complex I, J. Biol. Chem, vol.275, pp.223-228

A. Endo, A historical perspective on the discovery of statins, Proc Jpn Acad Ser B Phys Biol Sci, vol.86, pp.484-493, 2010.

A. Endo, M. Kuroda, and K. Tanzawa, Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity, FEBS Lett, vol.72, pp.323-326, 1976.

Z. Reiner, A. L. Catapano, G. De-backer, I. Graham, M. Taskinen et al., European Association for Cardiovascular Prevention & Rehabilitation

M. J. Chapman, ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Eur. Heart J, vol.32, pp.1769-1818, 2011.

E. Falk, Pathogenesis of Atherosclerosis, Journal of the American College of Cardiology, vol.47, pp.7-12, 2006.

, Atlas du diabète de la FID, 9e édition, 2019.

K. R. Feingold, C. Grunfeld, K. R. Endotext, B. Feingold, A. Anawalt et al., Introduction to Lipids and Lipoproteins, p.p, 2000.

B. A. Ference, J. G. Robinson, R. D. Brook, A. L. Catapano, M. J. Chapman et al., Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes, N. Engl. J. Med, vol.375, pp.2144-2153, 2016.

B. A. Ference, H. N. Ginsberg, I. Graham, K. K. Ray, C. J. Packard et al., Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies, 2017.

, Eur Heart J, vol.38, pp.2459-2472

E. Ferrannini, A. Natali, P. Bell, P. Cavallo-perin, N. Lalic et al., Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR), J. Clin. Invest, vol.100, pp.1166-1173, 1997.

C. J. Fielding, V. G. Shore, and P. E. Fielding, A protein cofactor of lecithin:cholesterol acyltransferase, Biochem. Biophys. Res. Commun, vol.46, pp.1493-1498, 1972.

A. V. Finn, M. Nakano, J. Narula, F. D. Kolodgie, and R. Virmani, Concept of vulnerable/unstable plaque, Arterioscler. Thromb. Vasc. Biol, vol.30, pp.1282-1292, 2010.

T. S. Fisher, P. L. Surdo, S. Pandit, M. Mattu, J. C. Santoro et al., Effects of pH and Low Density Lipoprotein (LDL) on PCSK9-dependent LDL Receptor Regulation, J. Biol. Chem, vol.282, pp.20502-20512, 2007.

K. Fitzgerald, S. White, A. Borodovsky, B. R. Bettencourt, A. Strahs et al., A Highly Durable RNAi Therapeutic Inhibitor of PCSK9, N. Engl. J. Med, vol.376, pp.41-51, 2017.

K. Folkers, P. Langsjoen, R. Willis, P. Richardson, L. J. Xia et al., Lovastatin decreases coenzyme Q levels in humans, PNAS, vol.87, pp.8931-8934, 1990.

F. Foufelle, B. D. Hegarty, A. Bobard, I. Hainault, P. Bossard et al., A new role for insulin in the control of energetic metabolism in liver, 2005.

M. Frank-kamenetsky, A. Grefhorst, N. N. Anderson, T. S. Racie, B. Bramlage et al., Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates, Proc. Natl. Acad. Sci. U.S.A, vol.105, pp.11915-11920, 2008.

Y. Fu, N. Luo, R. L. Klein, and W. T. Garvey, Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation, J. Lipid Res, vol.46, pp.1369-1379, 2005.

Z. Fu, E. R. Gilbert, and D. Liu, Regulation of Insulin Synthesis and Secretion and Pancreatic Beta-Cell Dysfunction in Diabetes, Curr Diabetes Rev, vol.9, pp.25-53, 2013.

G. Galabova, S. Brunner, G. Winsauer, C. Juno, B. Wanko et al., , 2014.

, Vaccines -An Approach for Long-Term LDLc Management, PLOS ONE, vol.9, p.114469

C. K. Garcia, K. Wilund, M. Arca, G. Zuliani, R. Fellin et al., Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein, Science, vol.292, pp.1394-1398, 2001.

B. Gatta, , 2008.

M. Gauthier, Z. Awan, A. Bouchard, J. Champagne, S. Tessier et al.,

P. Y. Garneau, R. Rabasa-lhoret, and N. G. Seidah, Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics, J Clin Lipidol, vol.12, pp.1027-1038, 2018.

G. Yong-jian and L. Peter, Progression of Atheroma, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.22, pp.1370-1380, 2002.

G. F. Gibbons, K. Islam, and R. J. Pease, Mobilisation of triacylglycerol stores, 2000.

, Biochim. Biophys. Acta, vol.1483, pp.37-57

P. Gilon, R. M. Shepherd, and J. C. Henquin, Oscillations of secretion driven by oscillations of cytoplasmic Ca2+ as evidences in single pancreatic islets, J. Biol. Chem, vol.268, pp.22265-22268, 1993.

M. A. Gimbrone, Vascular endothelium, hemodynamic forces, and atherogenesis, 1999.

, J. Pathol, vol.155, pp.1-5

H. N. Ginsberg, Lipoprotein metabolism and its relationship to atherosclerosis, Med. Clin. North Am, vol.78, pp.1-20, 1994.

A. Gisterå and G. K. Hansson, The immunology of atherosclerosis, Nature Reviews Nephrology, vol.13, pp.368-380, 2017.

R. P. Giugliano, F. Mach, K. Zavitz, C. Kurtz, J. Schneider et al., Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial, Clin Cardiol, vol.40, pp.59-65, 2017.

I. J. Goldberg, Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis, J. Lipid Res, vol.37, pp.693-707, 1996.

J. L. Goldstein and M. S. Brown, Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol, Proc. Natl. Acad. Sci. U.S.A, vol.70, pp.2804-2808, 1973.

J. L. Goldstein and M. S. Brown, Regulation of the mevalonate pathway, Nature, vol.343, pp.425-430, 1990.

J. L. Goldstein and M. S. Brown, History of Discovery: The LDL Receptor, Arterioscler Thromb Vasc Biol, vol.29, pp.431-438, 2009.

J. L. Goldstein and M. S. Brown, A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins, Cell, vol.161, pp.161-172, 2015.

D. A. Gordon, J. R. Wetterau, and R. E. Gregg, Microsomal triglyceride transfer protein: a protein complex required for the assembly of lipoprotein particles, Trends Cell Biol, vol.5, pp.317-321, 1995.

A. M. Gotto, H. J. Pownall, and R. J. Havel, , 1986.

, Meth. Enzymol, vol.128, pp.3-41

R. G. Gould, C. B. Taylor, J. S. Hagerman, I. Warner, and D. J. Campbell, , 1953.

I. Metabolism, Effect of Dietary Cholesterol on the Synthesis of Cholesterol in Dog Tissue in Vitro, J. Biol. Chem, vol.201, pp.519-528

M. J. Graham, K. M. Lemonidis, C. P. Whipple, A. Subramaniam, B. P. Monia et al., Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice, J. Lipid Res, vol.48, pp.763-767, 2007.

N. Gupta, N. Fisker, M. Asselin, M. Lindholm, C. Rosenbohm et al., A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo, PLoS One, vol.5, 2010.

C. Gustafsen, D. Olsen, J. Vilstrup, S. Lund, A. Reinhardt et al.,

C. B. Andersen, K. Weyer, and J. Li, Heparan sulfate proteoglycans present PCSK9 to the LDL receptor, Nature Communications, vol.8, pp.1-14, 2017.

H. Gylling and T. A. Miettinen, The effect of cholesterol absorption inhibition on low density lipoprotein cholesterol level, Atherosclerosis, vol.117, pp.305-308, 1995.

M. Hanefeld, P. Brunetti, G. H. Schernthaner, D. R. Matthews, and B. H. Charbonnel, , 2004.

, One-Year Glycemic Control With a Sulfonylurea Plus Pioglitazone Versus a Sulfonylurea Plus Metformin in Patients With Type 2 Diabetes, Diabetes Care, vol.27, pp.141-147

M. Hao, W. S. Head, S. C. Gunawardana, A. H. Hasty, and D. W. Piston, Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction, Diabetes, vol.56, pp.2328-2338, 2007.

R. J. Havel, J. P. Kane, and M. L. Kashyap, Interchange of apolipoproteins between chylomicrons and high density lipoproteins during alimentary lipemia in man, J. Clin. Invest, vol.52, pp.32-38, 1973.

T. Head, S. Daunert, and P. J. Goldschmidt-clermont, The Aging Risk and Atherosclerosis: A Fresh Look at Arterial Homeostasis, 2017.

A. M. Hebbachi and G. F. Gibbons, Microsomal membrane-associated apoB is the direct precursor of secreted VLDL in primary cultures of rat hepatocytes, J. Lipid Res, vol.42, pp.1609-1617, 2001.

U. Hedin, B. A. Bottger, J. Luthman, S. Johansson, and J. Thyberg, A substrate of the cell-attachment sequence of fibronectin (Arg-Gly-Asp-Ser) is sufficient to promote transition of arterial smooth muscle cells from a contractile to a synthetic phenotype, Dev. Biol, vol.133, pp.489-501, 1989.

D. Hinnen, Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes, Diabetes Spectrum, vol.30, pp.202-210, 2017.

J. A. Hirst, A. J. Farmer, A. Dyar, T. W. Lung, and R. J. Stevens, Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis, 2013.

, Diabetologia, vol.56, pp.973-984

H. H. Hobbs, M. S. Brown, and J. L. Goldstein, Molecular genetics of the LDL receptor gene in familial hypercholesterolemia, Human Mutation, vol.1, pp.445-466, 1992.

J. D. Horton, J. L. Goldstein, and M. S. Brown, SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver, J Clin Invest, vol.109, pp.1125-1131, 2002.

J. D. Horton, N. A. Shah, J. A. Warrington, N. N. Anderson, S. W. Park et al., Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes, Proc. Natl. Acad. Sci. U.S.A, vol.100, pp.12027-12032, 2003.

G. K. Hovingh, M. H. Davidson, J. J. Kastelein, and A. M. Connor, Diagnosis and treatment of familial hypercholesterolaemia, Eur. Heart J, vol.34, pp.962-971, 2013.

D. S. Hsia, O. Grove, and W. T. Cefalu, An Update on SGLT2 Inhibitors for the Treatment of Diabetes Mellitus, Curr Opin Endocrinol Diabetes Obes, vol.24, pp.73-79, 2017.

Z. Z. Htike, F. Zaccardi, D. Papamargaritis, D. R. Webb, K. Khunti et al., , 2017.

, Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis, Diabetes Obes Metab, vol.19, pp.524-536

, RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects -Full Text View -ClinicalTrials

, RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects -Full Text View -ClinicalTrials

, NCT02508896 Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects -Full Text View -ClinicalTrials.gov

, Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003 -Full Text View -ClinicalTrials

F. B. Hu, J. E. Manson, M. J. Stampfer, G. Colditz, S. Liu et al.,

, Lifestyle, and the Risk of Type 2 Diabetes Mellitus in Women, New England Journal of Medicine, vol.345, pp.790-797

D. Y. Hui and P. N. Howles, Molecular mechanisms of cholesterol absorption and transport in the intestine, Semin. Cell Dev. Biol, vol.16, pp.183-192, 2005.

E. Ikonen, Cellular cholesterol trafficking and compartmentalization, Nat. Rev. Mol. Cell Biol, vol.9, pp.125-138, 2008.

W. Insull, The pathology of atherosclerosis: plaque development and plaque responses to medical treatment, Am. J. Med, vol.122, pp.3-14, 2009.

T. S. Investigators, A. R. , and C. L. , High-Dose Atorvastatin after Stroke or Transient Ischemic Attack, 2009.

C. Ionescu-tirgoviste, P. A. Gagniuc, E. Gubceac, L. Mardare, I. Popescu et al.,

M. Militaru, A 3D map of the islet routes throughout the healthy human pancreas, 2015.

Z. Iqbal, S. Dhage, J. B. Mohamad, A. Abdel-razik, R. Donn et al.,

S. Adam and B. Isa, Efficacy and safety of PCSK9 monoclonal antibodies, Expert Opin Drug Saf, vol.18, pp.1191-1201, 2019.

M. Ishikawa, Y. Iwasaki, S. Yatoh, T. Kato, S. Kumadaki et al.,

T. Matsuzaka, Y. Nakagawa, and N. Yahagi, Cholesterol accumulation and diabetes in pancreatic ?-cell-specific SREBP-2 transgenic mice: a new model for lipotoxicity, J. Lipid Res, vol.49, pp.2524-2534, 2008.

H. Jang, S. E. Lee, J. Yang, H. Lee, D. Shin et al., Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9, Eur Heart J, vol.41, pp.239-252, 2020.

E. Jansen, T. A. Ayoubi, S. M. Meulemans, W. J. Ven, and . De, , 1995.

, Neuroendocrine-specific Expression of the Human Prohormone Convertase 1 Gene HORMONAL REGULATION OF TRANSCRIPTION THROUGH DISTINCT cAMP RESPONSE ELEMENTS, J. Biol. Chem, vol.270, pp.15391-15397

H. J. Jeong, H. Lee, K. Kim, Y. Kim, D. Yoon et al., Steroldependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterolregulatory element binding protein-2, J. Lipid Res, vol.49, pp.399-409, 2008.

P. Jones, S. Kafonek, I. Laurora, and D. Hunninghake, Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study), Am. J. Cardiol, vol.81, pp.582-587, 1998.

J. Jukema, Z. Wouter, E. Laurien, L. Bhatt-deepak, A. Bittner-vera et al.,

G. Heinz, G. Shaun, K. Yong-un, P. Robert, and R. ?eljko, Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES, Circulation, vol.140, pp.2054-2062, 2019.

I. Kaneko, Y. Hazama-shimada, and A. Endo, Inhibitory effects on lipid metabolism in cultured cells of ML-236B, a potent inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase, Eur. J. Biochem, vol.87, pp.313-321, 1978.

P. J. Kappelle, G. Lambert, B. Dahlbäck, L. B. Nielsen, and R. P. Dullaart, , 2011.

, Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects, Atherosclerosis, vol.214, pp.492-494

J. J. Kastelein, G. K. Hovingh, G. Langslet, M. T. Baccara-dinet, D. A. Gipe et al.,

J. Zhao, P. Minini, and M. Farnier, Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia, J Clin Lipidol, vol.11, pp.195-203, 2017.

K. Safi, U. Rahman-hammad, O. Victor, R. Haris, M. Khan et al., , 2019.

, Association of Lowering Low-Density Lipoprotein Cholesterol With Contemporary Lipid-Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Meta-Analysis, Journal of the American Heart Association, vol.8, 11581.

W. C. Knowler, E. Barrett-connor, S. E. Fowler, R. F. Hamman, J. M. Lachin et al., Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, and Diabetes Prevention Program Research Group, vol.346, pp.393-403, 2002.

J. Ko-min, J. A. Jeong, K. Y. Jung, K. Shin-hee, C. Songhee et al., Time-and Dose-Dependent Association of Statin Use With Risk of Clinically Relevant New-Onset Diabetes Mellitus in Primary Prevention: A Nationwide Observational Cohort Study, Journal of the American Heart Association, vol.8, 2019.

K. Kobayashi, K. Oka, T. Forte, B. Ishida, B. Teng et al.,

L. Chan, Reversal of hypercholesterolemia in low density lipoprotein receptor knockout mice by adenovirus-mediated gene transfer of the very low density lipoprotein receptor, J. Biol. Chem, vol.271, pp.6852-6860, 1996.

K. K. Koh, M. J. Quon, I. Sakuma, Y. Lee, S. Lim et al., Effects of simvastatin therapy on circulating adipocytokines in patients with hypercholesterolemia, 2011.

, J. Cardiol, vol.146, pp.434-437

L. M. Koppen, A. Whitaker, A. Rosene, and R. D. Beckett, Efficacy of Berberine Alone and in Combination for the Treatment of Hyperlipidemia: A Systematic Review, J Evid Based Complementary Altern Med, vol.22, pp.956-968, 2017.

J. K. Kruit, L. R. Brunham, C. B. Verchere, and M. R. Hayden, HDL and LDL cholesterol significantly influence beta-cell function in type 2 diabetes mellitus, Curr. Opin. Lipidol, vol.21, pp.178-185, 2010.

J. K. Kruit, P. H. Kremer, L. Dai, R. Tang, P. Ruddle et al., Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterolinduced impairment of beta cell function in mice, Diabetologia, vol.53, pp.1110-1119, 2010.

J. K. Kruit, N. Wijesekara, J. E. Fox, X. Dai, L. R. Brunham et al.,

A. J. Costin, R. Tang, and A. Bhattacharjee, Islet cholesterol accumulation due to loss of ABCA1 leads to impaired exocytosis of insulin granules, Diabetes, vol.60, pp.3186-3196, 2011.

A. J. Kwakernaak, G. Lambert, and R. P. Dullaart, Relationship of proprotein convertase subtilisin-kexin type 9 levels with resistin in lean and obese subjects, Clinical Biochemistry, vol.45, pp.1522-1524, 2012.

H. J. Kwon, T. A. Lagace, M. C. Mcnutt, J. D. Horton, and J. Deisenhofer, Molecular basis for LDL receptor recognition by PCSK9, Proc. Natl. Acad. Sci. U.S.A, vol.105, pp.1820-1825, 2008.

A. Lafont, Basic aspects of plaque vulnerability, Heart, vol.89, pp.1262-1267, 2003.

T. A. Lagace, D. E. Curtis, R. Garuti, M. C. Mcnutt, S. W. Park et al., Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice, J. Clin. Invest, vol.116, pp.2995-3005, 2006.

S. G. Lakoski, T. A. Lagace, J. C. Cohen, J. D. Horton, and H. H. Hobbs, Genetic and Metabolic Determinants of Plasma PCSK9 Levels, J Clin Endocrinol Metab, vol.94, pp.2537-2543, 2009.

F. Lalanne, G. Lambert, M. J. Amar, M. Chétiveaux, Y. Zaïr et al., Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells, J. Lipid Res, vol.46, pp.1312-1319, 2005.

G. Lambert, Unravelling the functional significance of PCSK9, Curr. Opin. Lipidol, vol.18, pp.304-309, 2007.

G. Lambert, N. Ancellin, F. Charlton, D. Comas, J. Pilot et al., Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment, Clin. Chem, vol.54, pp.1038-1045, 2008.

G. Lambert, B. Sjouke, B. Choque, J. J. Kastelein, and G. K. Hovingh, The PCSK9 decade, J. Lipid Res, vol.53, pp.2515-2524, 2012.

G. Lambert, F. Petrides, M. Chatelais, D. J. Blom, B. Choque et al., Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects, J. Am. Coll. Cardiol, vol.63, pp.2365-2373, 2014.

C. Landlinger, M. G. Pouwer, C. Juno, J. W. Van-der-hoorn, E. J. Pieterman et al.,

G. Staffler, H. M. Princen, and G. Galabova, The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice, Eur Heart J, vol.38, pp.2499-2507, 2017.

C. Langhi, C. Le-may, V. Gmyr, B. Vandewalle, J. Kerr-conte et al.,

P. Costet and B. Cariou, PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion, Biochem. Biophys. Res. Commun, vol.390, pp.1288-1293, 2009.

P. A. Lapchak, Hemorrhagic transformation following ischemic stroke: Significance, causes, and relationship to therapy and treatment, Curr Neurol Neurosci Rep, vol.2, pp.38-43, 2002.

A. Lavecchia and C. Cerchia, Recent advances in developing PCSK9 inhibitors for lipid-lowering therapy, Future Med Chem, vol.11, pp.423-441, 2019.

C. J. Lee, Y. Lee, S. W. Park, K. J. Kim, S. Park et al.,

Y. Jang, Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects, Metab. Clin. Exp, vol.62, pp.845-850, 2013.

S. Leigh, M. Futema, R. Whittall, A. Taylor-beadling, M. Williams et al., The UCL low-density lipoprotein receptor gene variant database: pathogenicity update, J. Med. Genet, vol.54, pp.217-223, 2017.

H. Li, B. Dong, S. W. Park, H. Lee, W. Chen et al., Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine, J. Biol. Chem, vol.284, pp.28885-28895, 2009.

J. Li, C. Tumanut, J. Gavigan, W. Huang, E. N. Hampton et al.,

J. W. Trauger, G. Spraggon, and S. A. Lesley, Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity, Biochem. J, vol.406, pp.203-207, 2007.

H. Liang, J. Chaparro-riggers, P. Strop, T. Geng, J. E. Sutton et al.,

J. Dilley and J. Yu, Proprotein Convertase Substilisin/Kexin Type 9 Antagonism Reduces Low-Density Lipoprotein Cholesterol in Statin-Treated Hypercholesterolemic Nonhuman Primates, J Pharmacol Exp Ther, vol.340, pp.228-236, 2012.

M. W. Lindholm, J. Elmén, N. Fisker, H. F. Hansen, R. Persson et al., PCSK9 LNA Antisense Oligonucleotides Induce Sustained Reduction of LDL Cholesterol in Nonhuman Primates, Mol Ther, vol.20, pp.376-381, 2012.

M. F. Linton, P. G. Yancey, S. S. Davies, W. G. Jerome, E. F. Linton et al., The Role of Lipids and Lipoproteins in Atherosclerosis, p.p, 2000.

L. A. Lotta, S. J. Sharp, S. Burgess, J. R. Perry, I. D. Stewart et al., Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Metaanalysis, JAMA, vol.316, pp.1383-1391, 2016.

A. J. Lusis, Atherosclerosis. Nature, vol.407, pp.233-241, 2000.

P. T. Ma, G. Gil, T. C. Südhof, D. W. Bilheimer, J. L. Goldstein et al., , 1986.

, Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits, Proc. Natl. Acad. Sci. U.S.A, vol.83, pp.8370-8374

F. Mach, C. Baigent, A. L. Catapano, K. C. Koskinas, M. Casula et al., 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskThe Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS), Eur Heart J, 2019.

A. K. Madiraju, D. M. Erion, Y. Rahimi, X. Zhang, D. T. Braddock et al., , 2014.

A. D. Marais, Familial Hypercholesterolaemia, Clin Biochem Rev, vol.25, pp.49-68, 2004.

P. Marchetti, M. Bugliani, V. De-tata, M. Suleiman, and L. Marselli, Pancreatic Beta Cell Identity in Humans and the Role of Type 2 Diabetes, Front Cell Dev Biol, vol.5, 2017.

L. O. Martinez, V. Georgeaud, C. Rolland, X. Collet, F. Tercé et al., Characterization of two high-density lipoprotein binding sites on porcine hepatocyte plasma membranes: contribution of scavenger receptor class B type I (SR-BI) to the lowaffinity component, Biochemistry, vol.39, pp.1076-1082, 2000.

D. P. Mason, R. D. Kenagy, D. Hasenstab, D. F. Bowen-pope, R. A. Seifert et al., Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery, Circ. Res, vol.85, pp.1179-1185, 1999.

K. N. Maxwell and J. L. Breslow, Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype, Proc. Natl. Acad. Sci. U.S.A, vol.101, pp.7100-7105, 2004.

K. N. Maxwell, R. E. Soccio, E. M. Duncan, E. Sehayek, and J. L. Breslow, Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterolfed mice, J. Lipid Res, vol.44, pp.2109-2119, 2003.

K. N. Maxwell, E. A. Fisher, and J. L. Breslow, Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment, Proc. Natl. Acad. Sci. U.S.A, vol.102, pp.2069-2074, 2005.

J. Mayne, A. Raymond, A. Chaplin, M. Cousins, N. Kaefer et al., Plasma PCSK9 levels correlate with cholesterol in men but not in women, Biochem. Biophys. Res. Commun, vol.361, pp.451-456, 2007.

M. Mbikay, F. Sirois, J. Mayne, G. Wang, A. Chen et al., PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities, FEBS Lett, vol.584, pp.701-706, 2010.

J. M. Mckenney, M. J. Koren, D. J. Kereiakes, C. Hanotin, A. Ferrand et al., Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy, J. Am. Coll. Cardiol, vol.59, pp.2344-2353, 2012.

M. C. Mcnutt, T. A. Lagace, and J. D. Horton, Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells, J. Biol. Chem, vol.282, pp.20799-20803, 2007.

J. B. Meigs, L. A. Cupples, and P. W. Wilson, Parental transmission of type 2 diabetes: the Framingham Offspring Study, Diabetes, vol.49, pp.2201-2207, 2000.

J. Miao, P. V. Manthena, M. E. Haas, A. V. Ling, D. Shin et al.,

J. Liu and S. B. Biddinger, Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9, Arterioscler. Thromb. Vasc. Biol, vol.35, pp.1589-1596, 2015.

R. A. Miller, Q. Chu, J. Xie, M. Foretz, B. Viollet et al., Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP, Nature, vol.494, pp.256-260, 2013.

T. Mitchell, G. Chao, D. Sitkoff, F. Lo, H. Monshizadegan et al., , 2014.

, Small Protein Biologic Alternative to PCSK9 Antibodies for Low-Density Lipoprotein Lowering, J Pharmacol Exp Ther, vol.350, pp.412-424

D. Morrone, W. S. Weintraub, P. P. Toth, M. E. Hanson, R. S. Lowe et al., Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials, Atherosclerosis, vol.223, pp.251-261, 2012.

D. Mozaffarian, E. J. Benjamin, A. S. Go, D. K. Arnett, M. J. Blaha et al., Heart disease and stroke statistics--2015 update: a report from the American Heart Association, vol.131, pp.29-322, 2015.

A. J. Murphy, L. E. Macdonald, S. Stevens, M. Karow, A. T. Dore et al., Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice, Proc. Natl. Acad. Sci. U.S.A, vol.111, pp.5153-5158, 2014.

M. Mytilinaiou, I. Kyrou, M. Khan, D. K. Grammatopoulos, and H. S. Randeva, , 2018.

F. Hypercholesterolemia, New Horizons for Diagnosis and Effective Management, Front Pharmacol, vol.9

M. Nakata, S. Nagasaka, I. Kusaka, H. Matsuoka, S. Ishibashi et al., Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control, Diabetologia, vol.49, pp.1881-1892, 2006.

N. Rossi, P. , T. Isabella, P. Dilip, N. Clare et al.,

. David, S. Van-heyningen-charles, and K. Anne, Severe Hypercholesterolemia in Four British Families With the D374Y Mutation in the PCSK9 Gene, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.25, pp.2654-2660, 2005.

C. Napoli, F. P. D'armiento, F. P. Mancini, A. Postiglione, J. L. Witztum et al., Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions, J. Clin. Invest, vol.100, pp.2680-2690, 1997.

F. K. Ndiaye, A. Ortalli, M. Canouil, M. Huyvaert, C. Salazar-cardozo et al.,

M. Verbanck, V. Pawlowski, R. Boutry, and E. Durand, Expression and functional assessment of candidate type 2 diabetes susceptibility genes identify four new genes contributing to human insulin secretion, Mol Metab, vol.6, pp.459-470, 2017.

T. Noguchi, J. Kobayashi, K. Yagi, A. Nohara, N. Yamaaki et al.,

M. Kawashiri and H. Tada, Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover study, Atherosclerosis, vol.217, pp.165-170, 2011.

B. G. Nordestgaard, M. J. Chapman, S. E. Humphries, H. N. Ginsberg, L. Masana et al., Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society, Eur. Heart J, vol.34, pp.3478-3490, 2013.

T. Nozue, Lipid Lowering Therapy and Circulating PCSK9 Concentration, 2017.

, Atheroscler Thromb, vol.24, pp.895-907

D. T. Odom, N. Zizlsperger, D. B. Gordon, G. W. Bell, N. J. Rinaldi et al., Control of Pancreas and Liver Gene Expression by HNF Transcription Factors, Science, vol.303, pp.1378-1381, 2004.

W. H. Organization, Definition, diagnosis and classification of diabetes mellitus and its complications : report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus, 1999.

L. Ose, , 2002.

, Tidsskr. Nor. Laegeforen, vol.122, pp.924-925

R. Pahwa, J. , and I. , Atherosclerosis. In StatPearls, 2019.

S. W. Park, Y. Moon, and J. D. Horton, Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver, J. Biol. Chem, vol.279, pp.50630-50638, 2004.

M. Paseban, A. E. Butler, and A. Sahebkar, Mechanisms of statin-induced new-onset diabetes, Journal of Cellular Physiology, vol.234, pp.12551-12561, 2019.

N. M. Pattnaik, A. Montes, L. B. Hughes, and D. B. Zilversmit, Cholesteryl ester exchange protein in human plasma isolation and characterization, Biochim. Biophys. Acta, vol.530, pp.428-438, 1978.

J. E. Pessin and A. R. Saltiel, Signaling pathways in insulin action: molecular targets of insulin resistance, J Clin Invest, vol.106, pp.165-169, 2000.

B. A. Phan, T. D. Dayspring, and P. P. Toth, Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag, vol.8, pp.415-427, 2012.

C. Piera-mardemootoo, P. Lambert, and J. Faillie, Efficacy of metformin on glycemic control and weight in drug-naive type 2 diabetes mellitus patients: A systematic review and meta-analysis of placebo-controlled randomized trials, Therapie, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02341129

E. P. Van-poelgeest, M. R. Hodges, M. Moerland, Y. Tessier, A. A. Levin et al., Antisensemediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial, Br J Clin Pharmacol, vol.80, pp.1350-1361, 2015.

S. Poirier and G. Mayer, The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol, Drug Des Devel Ther, vol.7, pp.1135-1148, 2013.

S. Poirier, M. Mamarbachi, W. Chen, A. S. Lee, and G. Mayer, GRP94 Regulates Circulating Cholesterol Levels through Blockade of PCSK9-Induced LDLR Degradation, Cell Rep, vol.13, pp.2064-2071, 2015.

P. Proks, F. Reimann, N. Green, F. Gribble, A. et al., Sulfonylurea Stimulation of Insulin Secretion, Diabetes, vol.51, pp.368-376, 2002.

D. J. Rader and H. H. Hobbs, Disorders of Lipoprotein Metabolism, 2016.

J. Rahier, Y. Guiot, R. M. Goebbels, C. Sempoux, and J. C. Henquin, Pancreatic betacell mass in European subjects with type 2 diabetes, Diabetes Obes Metab, vol.10, pp.32-42, 2008.

S. Ramin-mangata, V. Blanchard, L. , and G. , Key aspects of PCSK9 inhibition beyond LDL lowering, Curr. Opin. Lipidol, vol.29, pp.453-458, 2018.

S. Ramin-mangata, M. Wargny, M. Pichelin, C. L. May, A. Thédrez et al., Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes, Atherosclerosis, vol.293, pp.49-56, 2020.

S. Rashid, D. E. Curtis, R. Garuti, N. N. Anderson, Y. Bashmakov et al., Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9, PNAS, vol.102, pp.5374-5379, 2005.

P. Ravassard, Y. Hazhouz, S. Pechberty, E. Bricout-neveu, M. Armanet et al., A genetically engineered human pancreatic ? cell line exhibiting glucose-inducible insulin secretion, J. Clin. Invest, vol.121, pp.3589-3597, 2011.

A. Rawshani, A. Rawshani, S. Franzén, B. Eliasson, A. Svensson et al.,

D. K. Mcguire, N. Sattar, A. Rosengren, and S. Gudbjörnsdottir, Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes, New England Journal of Medicine, vol.376, pp.1407-1418, 2017.

K. K. Ray, R. M. Stoekenbroek, D. Kallend, T. Nishikido, L. A. Leiter et al.,

R. S. Wright, P. L. Wijngaard, and J. J. Kastelein, Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial, JAMA Cardiol, vol.4, pp.1067-1075, 2019.

K. K. Ray, H. M. Colhoun, M. Szarek, M. Baccara-dinet, D. L. Bhatt et al., Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial, The Lancet Diabetes & Endocrinology, vol.7, pp.618-628, 2019.

P. M. Ridker, A. Pradhan, J. G. Macfadyen, P. Libby, and R. J. Glynn, Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial, The Lancet, vol.380, pp.565-571, 2012.

P. M. Ridker, J. Revkin, P. Amarenco, R. Brunell, M. Curto et al., Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01896435

J. G. Robinson, M. Farnier, M. Krempf, J. Bergeron, G. Luc et al.,

G. Langslet, F. J. Raal, and M. El-shahawy, Efficacy and safety of alirocumab in reducing lipids and cardiovascular events, N. Engl. J. Med, vol.372, pp.1489-1499, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02641589

P. V. Röder, B. Wu, Y. Liu, and W. Han, Pancreatic regulation of glucose homeostasis, 2016.

, Exp Mol Med, vol.48, p.219

M. Roehrich, V. Mooser, V. Lenain, J. Herz, J. Nimpf et al., Insulin-secreting beta-cell dysfunction induced by human lipoproteins, J. Biol. Chem, vol.278, pp.18368-18375, 2003.

P. Rorsman and F. M. Ashcroft, Pancreatic ?-Cell Electrical Activity and Insulin Secretion: Of Mice and Men, Physiol Rev, vol.98, pp.117-214, 2018.

P. Rorsman and E. Renström, Insulin granule dynamics in pancreatic beta cells, Diabetologia, vol.46, pp.1029-1045, 2003.

S. B. Rosenblum, T. Huynh, A. Afonso, H. R. Davis, N. Yumibe et al., Discovery of 1-(4-fluorophenyl)-(3R), 1998.

, -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption, J. Med. Chem, vol.4, issue.4, pp.973-980

R. S. Rosenson and C. C. Tangney, Antiatherothrombotic Properties of Statins: Implications for Cardiovascular Event Reduction, JAMA, vol.279, pp.1643-1650, 1998.

R. S. Rosenson, R. A. Hegele, S. Fazio, and C. P. Cannon, The Evolving Future of PCSK9 Inhibitors, Journal of the American College of Cardiology, vol.72, pp.314-329, 2018.

R. Ross, Atherosclerosis--an inflammatory disease, N. Engl. J. Med, vol.340, pp.115-126, 1999.

E. M. Roth, Alirocumab for low-density lipoprotein cholesterol lowering, Future Cardiol, vol.15, pp.17-29, 2019.

E. M. Roth, J. M. Mckenney, C. Hanotin, G. Asset, and E. A. Stein, Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia, New England Journal of Medicine, vol.367, pp.1891-1900, 2012.

S. Rütti, J. A. Ehses, R. A. Sibler, R. Prazak, L. Rohrer et al., Low-and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic betacells, Endocrinology, vol.150, pp.4521-4530, 2009.

M. S. Sabatine, R. P. Giugliano, A. C. Keech, N. Honarpour, S. D. Wiviott et al.,

J. F. Kuder, H. Wang, T. Liu, and S. M. Wasserman, Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease, N. Engl. J. Med, vol.376, pp.1713-1722, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01896445

M. S. Sabatine, L. A. Leiter, S. D. Wiviott, R. P. Giugliano, P. Deedwania et al.,

S. A. Murphy, J. F. Kuder, I. Gouni-berthold, and B. S. Lewis, Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial, Lancet Diabetes Endocrinol, vol.5, pp.941-950, 2017.

M. S. Sabatine, L. A. Leiter, S. D. Wiviott, R. P. Giugliano, P. Deedwania et al.,

S. A. Murphy, J. F. Kuder, I. Gouni-berthold, and B. S. Lewis, Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial, Lancet Diabetes Endocrinol, vol.5, pp.941-950, 2017.

S. M. Sabesin and S. Frase, Electron microscopic studies of the assembly, intracellular transport, and secretion of chylomicrons by rat intestine, J. Lipid Res, vol.18, pp.496-511, 1977.

A. Sahebkar, L. E. Simental-mendía, F. Guerrero-romero, J. Golledge, and G. F. Watts, Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials, Diabetes Obes Metab, vol.17, pp.1042-1055, 2015.

N. Sattar, P. P. Toth, D. J. Blom, M. J. Koren, H. Soran et al.,

R. Somaratne and D. Preiss, Effect of the Proprotein Convertase Subtilisin/Kexin Type, 2017.

, Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus, Am. J. Cardiol, vol.120, pp.1521-1527

A. F. Schmidt, D. I. Swerdlow, M. V. Holmes, R. S. Patel, Z. Fairhurst-hunter et al.,

F. P. Hartwig, B. L. Horta, E. Hyppönen, and C. Power, PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study, Lancet Diabetes Endocrinol, vol.5, pp.97-105, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01833114

A. F. Schmidt, M. V. Holmes, D. Preiss, D. I. Swerdlow, S. Denaxas et al., Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9, BMC Cardiovascular Disorders, vol.19, p.240, 2019.

S. A. Schreiber, K. Ferlinz, and T. Haak, The Long-Term Efficacy of Insulin Glargine Plus Oral Antidiabetic Agents in a 32-Month Observational Study of Everyday Clinical Practice, Diabetes Technology & Therapeutics, vol.10, pp.121-127, 2008.

C. I. Schroeder, J. E. Swedberg, J. M. Withka, K. J. Rosengren, M. Akcan et al., Design and Synthesis of Truncated EGF-A Peptides that Restore LDL-R Recycling in the Presence of PCSK9 In Vitro, Chemistry & Biology, vol.21, pp.284-294, 2014.

G. G. Schwartz, P. G. Steg, M. Szarek, D. L. Bhatt, V. A. Bittner et al., Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome, New England Journal of Medicine, vol.379, pp.2097-2107, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02059074

N. G. Seidah, S. Benjannet, L. Wickham, J. Marcinkiewicz, S. B. Jasmin et al., The secretory proprotein convertase neural apoptosisregulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation, Proc. Natl, 2003.

, Acad. Sci. U.S.A, vol.100, pp.928-933

L. Shan, L. Pang, R. Zhang, N. J. Murgolo, H. Lan et al., PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide, Biochemical and Biophysical Research Communications, vol.375, pp.69-73, 2008.

M. D. Shapiro, H. Tavori, and S. Fazio, PCSK9: From Basic Science Discoveries to Clinical Trials, Circ Res, vol.122, pp.1420-1438, 2018.

R. J. Shaw, K. A. Lamia, D. Vasquez, S. Koo, N. Bardeesy et al., The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin, Science, vol.310, pp.1642-1646, 2005.

B. Silver, K. Ramaiya, S. B. Andrew, O. Fredrick, S. Bajaj et al.,

K. Claudine and A. Makhoba, EADSG Guidelines: Insulin Therapy in Diabetes, Diabetes Ther, vol.9, pp.449-492, 2018.

M. G. Silverman, B. A. Ference, K. Im, S. D. Wiviott, R. P. Giugliano et al., Association Between Lowering LDL-C and, 2016.

, Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis, JAMA, vol.316, pp.1289-1297

O. Sizar, S. Khare, and R. Talati, Statin Medications. In StatPearls, 2020.

J. S. Skyler, G. L. Bakris, E. Bonifacio, T. Darsow, R. H. Eckel et al., Differentiation of Diabetes by Pathophysiology, vol.66, pp.241-255, 2017.

A. D. Sniderman, S. Tsimikas, and S. Fazio, The Severe Hypercholesterolemia Phenotype: Clinical Diagnosis, Management, and Emerging Therapies, Journal of the American College of Cardiology, vol.63, pp.1935-1947, 2014.

N. Sodhi and D. L. Brown, 7 -Pathophysiology of Acute Coronary Syndromes: Plaque Rupture and Atherothrombosis, Content Repository Only!), pp.68-80, 2019.

R. Song, Mechanism of Metformin: A Tale of Two Sites, Diabetes Care, vol.39, pp.187-189, 2016.

D. T. Stein, S. Devaraj, D. Balis, B. Adams-huet, J. et al., Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia, 2001.

, Arterioscler. Thromb. Vasc. Biol, vol.21, pp.2026-2031

E. A. Stein, S. Mellis, G. D. Yancopoulos, N. Stahl, D. Logan et al., Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol, New England Journal of Medicine, vol.366, pp.1108-1118, 2012.

E. A. Stein, S. Kasichayanula, T. Turner, T. Kranz, U. Arumugam et al.,

, Ldl Cholesterol Reduction with Bms-962476, an Adnectin Inhibitor of Pcsk9: Results of a Single Ascending Dose Study, J Am Coll Cardiol, vol.63, p.1372

D. J. Steiner, A. Kim, K. Miller, and M. Hara, Pancreatic islet plasticity: Interspecies comparison of islet architecture and composition, Islets, vol.2, pp.135-145, 2010.

A. Taki, A. Kermani, S. M. Ranjbarnavazi, and A. Pourmodheji, Chapter 4 -Overview of Different Medical Imaging Techniques for the Identification of Coronary Atherosclerotic Plaques, Computing and Visualization for Intravascular Imaging and Computer-Assisted Stenting, pp.79-106, 2017.

S. S. Talathi, Y. , and M. , Anatomy, Abdomen and Pelvis, Pancreas. In StatPearls, 2020.

N. A. Thornberry and B. Gallwitz, Mechanism of action of inhibitors of dipeptidylpeptidase-4 (DPP-4), Best Practice & Research Clinical Endocrinology & Metabolism, vol.23, pp.479-486, 2009.

K. M. Timms, S. Wagner, M. E. Samuels, K. Forbey, H. Goldfine et al., A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree, Hum. Genet, vol.114, pp.349-353, 2004.

P. P. Toth, A. M. Patti, R. V. Giglio, D. Nikolic, G. Castellino et al., Management of Statin Intolerance in 2018: Still More Questions Than Answers, Am J Cardiovasc Drugs, vol.18, pp.157-173, 2018.

P. P. Toth, N. Sattar, D. J. Blom, S. S. Martin, S. R. Jones et al., , 2018.

, American Journal of Cardiology, vol.121, pp.308-314

S. Tsimikas, P. L. Gordts, C. Nora, C. Yeang, and J. L. Witztum, Statin therapy increases lipoprotein(a) levels, Eur. Heart J, 2019.

V. Valenti, D. Noto, A. Giammanco, F. Fayer, R. Spina et al., PCSK9-D374Y mediated LDL-R degradation can be functionally inhibited by EGF-A and truncated EGF-A peptides: An in vitro study, Atherosclerosis, vol.292, pp.209-214, 2020.

M. Varret and J. Rabès, Missense Mutation in the LDLR Gene: A Wide Spectrum in the Severity of Familial Hypercholesterolemia, 2012.

M. Varret, J. P. Rabès, B. Saint-jore, A. Cenarro, J. C. Marinoni et al.,

M. Krempf, M. Coulon, and R. Thiart, A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32, Am. J. Hum. Genet, vol.64, pp.1378-1387, 1999.

M. L. Vega-monroy, . De-la, and C. Fernandez-mejia, Beta-Cell Function and Failure in Type 1 Diabetes. Type 1 Diabetes -Pathogenesis, Genetics and Immunotherapy, 2011.

B. Viollet, B. Guigas, N. S. Garcia, J. Leclerc, M. Foretz et al., Cellular and molecular mechanisms of metformin: an overview, Clinical Science, vol.122, p.253, 1979.
URL : https://hal.archives-ouvertes.fr/inserm-00658070

R. Virmani, F. D. Kolodgie, A. P. Burke, A. Farb, and S. M. Schwartz, Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions, Arterioscler. Thromb. Vasc. Biol, vol.20, pp.1262-1275, 2000.

K. Wang, C. Liu, T. Chao, C. Huang, C. Wu et al., Statins, risk of diabetes, and implications on outcomes in the general population, J. Am. Coll. Cardiol, vol.60, pp.1231-1238, 2012.

N. Wang, D. L. Silver, P. Costet, and A. R. Tall, Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1, J. Biol. Chem, vol.275, pp.33053-33058, 2000.

G. C. Weir and S. Bonner-weir, Finally! A human pancreatic ? cell line, J. Clin. Invest, vol.121, pp.3395-3397, 2011.

G. Welder, I. Zineh, M. A. Pacanowski, J. S. Troutt, G. Cao et al., Highdose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol, J. Lipid Res, vol.51, pp.2714-2721, 2010.

C. Werner, M. M. Hoffmann, K. Winkler, M. Böhm, and U. Laufs, Vascul. Pharmacol, vol.62, pp.94-102, 2014.

, Cardiovascular diseases (CVDs), 2015.

G. Wilcox, Insulin and Insulin Resistance, Clin Biochem Rev, vol.26, pp.19-39, 2005.

, Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation, 2011.

F. Xia, L. Xie, A. Mihic, X. Gao, Y. Chen et al., , 2008.

, Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic beta-cells, Endocrinology, vol.149, pp.5136-5145

T. Yada, M. Nakata, T. Shiraishi, and M. Kakei, Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet ?-cells, British Journal of Pharmacology, vol.126, pp.1205-1213, 2009.

A. Yamamoto, H. Sudo, and A. Endo, Therapeutic effects of ML-236B in primary hypercholesterolemia, Atherosclerosis, vol.35, pp.259-266, 1980.

K. H. Yoon, S. H. Ko, J. H. Cho, J. M. Lee, Y. B. Ahn et al., Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea, J. Clin. Endocrinol. Metab, vol.88, pp.2300-2308, 2003.

S. Yusuf, S. Hawken, S. Ôunpuu, T. Dans, A. Avezum et al.,

P. Pais and J. Varigos, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study, The Lancet, vol.364, pp.937-952, 2004.

F. Zaccardi, D. R. Webb, Z. Z. Htike, D. Youssef, K. Khunti et al., , 2016.

, Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis, Diabetes Obes Metab, vol.18, pp.783-794

A. Zaid, A. Roubtsova, R. Essalmani, J. Marcinkiewicz, A. Chamberland et al., Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration, Hepatology, vol.48, pp.646-654, 2008.

N. Zelcer, C. Hong, R. Boyadjian, and P. Tontonoz, LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor, Science, vol.325, pp.100-104, 2009.

D. Zhang, T. A. Lagace, R. Garuti, Z. Zhao, M. Mcdonald et al., Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation, J. Biol. Chem, vol.282, pp.18602-18612, 2007.

L. Zhang, K. Reue, L. G. Fong, S. G. Young, and P. Tontonoz, Feedback regulation of cholesterol uptake by the LXR-IDOL-LDLR axis, Arterioscler Thromb Vasc Biol, vol.32, pp.2541-2546, 2012.

S. H. Zhang, R. L. Reddick, J. A. Piedrahita, and N. Maeda, Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E, Science, vol.258, pp.468-471, 1992.

Y. Zhang, L. Zhou, M. Kong-beltran, W. Li, P. Moran et al., Calcium-Independent Inhibition of PCSK9 by Affinity-Improved Variants of the LDL Receptor EGF(A) Domain, Journal of Molecular Biology, vol.422, pp.685-696, 2012.

F. Ziemke and C. S. Mantzoros, Adiponectin in insulin resistance: lessons from translational research1234, Am J Clin Nutr, vol.91, pp.258-261, 2010.

N. J. Van-der-zijl, G. H. Goossens, C. C. Moors, D. H. Van-raalte, and M. H. Muskiet,

P. J. Pouwels, E. E. Blaak, and M. Diamant, Ectopic fat storage in the pancreas, liver, and abdominal fat depots: impact on ?-cell function in individuals with impaired glucose metabolism, J. Clin. Endocrinol. Metab, vol.96, pp.459-467, 2011.